Exploring gut bacteria's role in pelvic cancer treatment
Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer
This study is trying to see how gut bacteria might affect how well patients with pelvic cancers respond to treatments like chemotherapy and radiotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 16 Years to 99 Years |
| Sex | All |
| Sponsor | University of Aberdeen Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Aberdeen, Scotland) |
| Trial ID | NCT05605353 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between gut microbiota and treatment responses in patients with pelvic cancers, including bladder, prostate, cervical, ovarian, womb, and colorectal cancers. Patients will provide fecal samples prior to their treatment, allowing researchers to analyze the gut bacteria profiles and their potential influence on radiotherapy and chemotherapy outcomes. The study is conducted at the University of Aberdeen and Aberdeen Royal Infirmary, leveraging their specialized microbiota laboratory and clinical facilities for comprehensive analysis.
Who should consider this trial
Good fit: Ideal candidates are patients over 16 years old being treated for pelvic cancers at NHS Grampian who are willing to consent.
Not a fit: Patients with malignancies from other sources or anatomical locations will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for pelvic cancer patients by personalizing therapies based on gut microbiota profiles.
How similar studies have performed: While the exploration of gut microbiota in cancer treatment is a growing field, this specific approach focusing on pelvic cancers is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients willing to consent 2. Any patient who is being treated in NHS Grampian for a pelvic cancer (Colorectal, urological or gynaecological) above 16 years of age Exclusion Criteria: 1. patients who are not willing to consent to be involved 2. Malignancies from other sources or anatomical locations 3. Patients who lack the understanding of the study to obtain appropriate levels of consen
Where this trial is running
Aberdeen, Scotland
- Aberdeen Royal Infirmary — Aberdeen, Scotland, United Kingdom (Recruiting)
Study contacts
- Principal investigator: George Ramsay, FRCS — University of Aberdeen
- Study coordinator: George Ramsay, FRCS
- Email: george.ramsay@abdn.ac.uk
- Phone: 03454566000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.